MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Synucleozid

CAS No. : 502139-01-7

MCE 站：Synucleozid

产品活性：Synucleozid (NSC 377363) 是可编码 α-突触核蛋白的 SNCA?mRNA 的有效抑制剂 (IC₅₀=1.5 μM)。Synucleozid 选择性靶向 α-synuclein mRNA 的 5'UTR 设计 IRE 位点，减少了加载到多核糖体中的 SNCA mRNA 的量，从而抑制了α-synuclein 蛋白的翻译。Synucleozid 有潜力用于帕金森病的相关研究。

研究领域：Cell Cycle/DNA Damage

作用靶点：DNA/RNA Synthesis

In Vitro: Synucleozid (0.25-1 μM; 24 hours) abrogates cytotoxicity induced by α-synuclein preformed fibrils, which act as seeds and recruit endogenous α-synuclein to aggregate.
Synucleozid (0-1 μM; 24 hours) binds to the A bulge near the base of the IRE hairpin, reduced levels of α-synuclein in a dose-dependent manner with an IC₅₀ of 500 nM, and inhibits α-synuclein protein expression in SH-SY5Y neuroblastoma cells.
Synucleozid (100 nM-100 μM; 24 hours) binds to 2-AP-labeled and native IRE RNA with similar affinities. It decreases 2-AP emission with an EC₅₀?value of 2.7 μM, recovery of 2-AP emissions is observed as a function of unlabeled?SNCA?IRE RNA (RNA-0) concentration, affording a competitive?K_d?of 1.5 μM.
Synucleozid (0.25-1 μM; 24 hours) decreases α-synuclein and other proteins that have IREs in their mRNA’s UTR including APP, PrP, Ferritin and TfR as a dose-dependent mannner. All panels is completed in SH-SY5Y cells, except for PrP protein which is assessed in Neuro-2A cells.

相关产品：Cycloheximide  |  Oxaliplatin  |  Gemcitabine  |  Actinomycin D  |  Mitomycin C  |  Bleomycin sulfate  |  Carboplatin  |  Cytarabine  |  Favipiravir  |  Methotrexate  |  Streptozocin  |  Anisomycin  |  Fludarabine  |  Thymidine  |  Epirubicin hydrochloride  |  Daunorubicin hydrochloride  |  Capecitabine  |  Hydroxyurea  |  Plicamycin  |  Urolithin A  |  Brequinar  |  Folic acid  |  ML216  |  Halofuginone  |  Floxuridine  |  Triciribine  |  Galidesivir hydrochloride  |  Adenine

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。